BioLineRx `Confident' on Schizophrehia Drug Trials

REPLAY VIDEO
Your next video will start in
Pause
  • Info

  • Comments

Nov. 28 (Bloomberg) -- BioLineRx Ltd. Chief Financial Officer Philip Serlin talks about the outlook for trials of the company's BL-1020 schizophrehia drug. He speaks from the Tel Aviv Stock Exchange with Maryam Nemazee on Bloomberg Television's "The Pulse." (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change